Boston, United States
Jnana Therapeutics is a clinical-stage biotechnology company utilizing its next-generation chemoproteomics RAPID platform to discover medications for highly validated, challenging-to-drug targets, addressing diseases with high unmet need. The company's focus lies in developing first- and best-in-class therapies to treat a wide range of diseases, including rare and immune-mediated diseases. Its lead program is a potential first-in-class oral approach, targeting an allosteric site on the phenylalanine transporter SLC6A19, catering to the treatment of phenylketonuria (PKU), a rare genetic metabolic disease.
Established in 2017 in the United States, Jnana has brought together scientific leaders in small molecule drug discovery and development, a highly experienced management team, and the backing of leading life science investors such as Bain Capital Life Sciences, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures, and AbbVie Ventures.
The company received a significant $107.00M Series C investment on 15 November 2022 from investors including Avalon Ventures, Polaris Partners, RA Capital Management, Versant Ventures, AbbVie Ventures, Bain Capital Life Sciences, and Pfizer Venture Investments.
For more information, please visit www.jnanatx.com and follow the company on Twitter and LinkedIn.
